Personalised cancer treatment comes closer to realityApril 20th, 2009 - 6:29 pm ICT by ANI
London, Apr 20 (ANI): Researchers have taken a step forward to bringing personalized cancer therapy within reach by using molecular profiling of the patients that can help identify specific treatments.
The study shows that molecular profiling of patients can identify specific treatments for individuals, helping keep their cancer in check for significantly longer periods, and in some cases even shrinking tumours.
During the research, the team recruited 66 patients at nine centres across the United States, including Scottsdale Heathcare.
All of the patients had previously experienced growth of their tumours while undergoing as many as two to six prior cancer treatments, including conventional chemotherapy.
However, after molecular profiling identified precise targets, new treatments were administered that resulted in patients experiencing significant periods of time when there was no progression of their cancer.
The treatments would be prescribed based on an individual’s specific genetic makeup. The type of drugs, dosages, their delivery and other treatment aspects - all are based on each patient’s individual medical needs.
The research team found that patients experienced varying levels of improvement. Among those with breast cancer, the period of progression-free survival increased for 44 percent of patients; for colorectal, 36 percent of patients; for ovarian, 20 percent of patients; and for miscellaneous cancers the improvement was seen in 16 percent of patients.
“With this trial, we are showing the power of personalized medicine using the tools we already have available to us,” said Dr. Von Hoff, Chief Scientific Officer of TGen Clinical Research Services (TCRS) at Scottsdale Healthcare.
“As these tools become more precise and more effective, the value of personalized medicine will increase,” he added.
“This trial is evidence of an important breakthrough in the treatment of cancer,” said David D. Halbert, Chairman and CEO of Caris Diagnostics.
The molecular profiling for this research study was performed by Caris Diagnostics (Caris Dx) in Phoenix.
The study was presented at 100th annual meeting of the American Association for Cancer Research in Denver. (ANI)
- Scientists make breakthrough in small-cell lung cancer - Jan 14, 2010
- Revolutionary drug brings new hope for adrenal cancer patients - Sep 23, 2009
- Novel non-invasive tests could help in early detection of cancer - May 04, 2011
- New drug that aims to 'seek and destroy' cancer identified - Oct 07, 2009
- Combo therapy may overcome Herceptin-resistant breast cancer - Mar 14, 2011
- Biosensor shows promise for cancer diagnosis - May 16, 2012
- Protein biomarkers in exhaled air to help detect lung cancer early - Feb 03, 2011
- Novel treatment gives hope to lymphoma, leukemia patients - Feb 27, 2010
- Indian, Australian experts working on new cancer treatment - Jan 07, 2011
- Potent anticancer drug isolated from weed - Jul 10, 2012
- Blood test for depression closer to reality - Jul 23, 2010
- New investigational drug targets pancreatic cancer cells - Sep 16, 2010
- Circulating tumour cells in blood up death risk in early-stage breast cancer patients - Dec 11, 2010
- Chemotherapy post-surgery 'may not be always necessary' - Nov 09, 2010
- Indian-origin scientist's finding offers hope for advanced cancer patients - Apr 06, 2011
Tags: breast cancer, cancer therapy, cancer treatment, cancer treatments, chemotherapy, clinical research services, colorectal, conventional chemotherapy, david d halbert, free survival, genetic makeup, heathcare, hoff, individual medical, precise targets, scottsdale healthcare, treatment aspects, treatment of cancer, tumours, type of drugs